Key hire
Atisama Therapeutics advances RB042 into multiple ascending dose cohorts of Phase 1 Trial and appoints Bernard Coulie as Chair of the Board
Atisama Therapeutics reports its Phase 1 trial of RB042 advancing into multiple ascending dose cohorts, and appoints experienced biopharma executive Bernard Coulie as chair of its board.